T-cell immune response cDNA 7 in allograft rejection and inflammation

Current Opinion in Investigational Drugs

Volumn 8, Issue 5, 2007, Pages 401-410

  Utku, Nalân ^a,b   Heinemann, Thomas ^c   Milford, Edgar L ^d  

^a GenPat77 AG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytotoxic T lymphocyte antigen 4; mAb; T cell immune response cDNA 7; T cell immune response gene 1; TNF ; Transplant rejection

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; OKT 3; T CELL IMMUNE RESPONSE COMPLEMENTARY DEOXYRIBONUCLEIC ACID 7 ANTIBODY; T CELL IMMUNE RESPONSE COMPLEMENTARY DEOXYRIBONUCLEIC ACID 7 PROTEIN; T LYMPHOCYTE ANTIGEN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTHRITIS; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY GRAFT REJECTION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 34247844377     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Utku N, Heinemann T, Tullius SG, Bulwin GC, Beinke S, Blumberg RS, Beato F, Randall J, Kojima R, Busconi L, Robertson ES et al: Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity (1998) 9(4):509-518. •• This study was the first to identify TIRC7 and its functional relevance in the context of immune activation in various in vitro and in vivo assays.
2. Liang P, Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (1992) 257(5072):967-971.
3. Dangond F, Hafler DA, Tong JK, Randall J, Kojima R, Utku N, Gullans SR: Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biphys Res Commun (1998) 242(3):648-652.
4. Utku N, Bulwin GC, Beinke S, Heinemann T, Beato F, Randall J, Schnieders B, Sandhoff K, Volk H-D, Milford E, Gullans SR: The human homologue of Drosophila cornichon protein is differentially expressed in alloactivated T cells. Biochim Biophys Acta (1999) 1449(3):203-210.
5. Heinemann T, Bulwin GC, Randall J, Schnieders B, Sandhoff K, Volk HD, Milford E, Gullans SR, Uktu N: Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics (1999) 57(3):398-406. • This paper describes the genomic organization and chromosomal localization of TIRC7, as well as the analysis of exon and intron boundaries in comparison with its splice variant OC116 relevant for the structural understanding of both proteins.
6. Schneider HS, da Rocha Dias S, Hu H, Rudd CE: A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling. Eur J Immunol (2001) 31(7):2042-2050.
7. Klabunde T, Hessler G: Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem (2002) 3(10):928-944.
8. Sexton PM, Christopoulos A: G protein-coupled receptor drug targets. Curr Pharm Des (2006) 12(14):1681-1682.
9. Li YP, Chen W, Stashenko P: Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem Biophys Res Commun (1996) 218(3):813-321. • The first demonstration of cDNA OC116 being isolated from a human osteoclastoma cell line and its restricted expression in cells obtained from human osteoblastoma and pancreas carcinoma cells is reported.
10. Smirnova AS, Morgun A, Shulzhenko N, Silva ID, Gerbase-DeLima M: Identification of new alternative splice events in the TCIRG1 gene in different human tissues. Biochem Biophys Res Commun (2005) 330(3):943-949.
11. Li YP, Chen W, Liang Y, Li W, Stashenko P: Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet (1999) 23(4):447-451. • Data obtained from OC116-deficient mice and the potential involvement of OC116 in the bone resorption processes are described.
12. Lee C, Ghoshal K, Beaman KD: Cloning of a cDNA or a T cell produced molecule with a putative immune regulatory role. Mol Immunol (1990) 27(11):1137-1144.
13. Manolson MF, Proteau D, Jones EW: Evidence for a conserved 95-120 kDa subunit associated with and essential for activity of V-ATPases. J Exp Biol (1992) 172:105-112.
14. Utku N, Heinemann T, Winter M, Bulwin GC, Schlawinsky M, Fraser P, Nieuwenhuis EE, Volk HD, Blumberg RS: Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice. Clin Exp Immunol (2006) 144(1):142-151. •• This paper reports the use of TIRC7 as a target expressed on T- and B-cells to develop innovative therapeutics for the treatment of inflammatory disease conditions such as RA.
15. Bulwin GC, Heinemann T, Bugge V, Winter M, Lohan A, Schlawinsky M, Schulze A, Wälter S, Sabat R, Schülein R, Wiesner B et al: TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol (2006) 177(10):6833-6841. •• The involvement of TIRC7 in early immune activation is demonstrated as an upstream regulator of the CTLA-4 associated with a location in the immune synapse.
16. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML: The immunological synapse. Annu Rev Immunol (2001) 19:375-396.
17. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML: The immunological synapse: A molecular machine controlling T cell activation. Science (1999) 285(5425):221-227.
18. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A: Three-dimensional segregation of supramolecular activation clusters in T cells. Nature (1998) 395(6697):82-86.
19. Egen JG, Allison JP: Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 16(1):23-35.
20. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS: Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 4(6):535-543.
21. Kumamoto Y, Tomschegg A, Bennai-Sanfourche F, Boerner A, Kaser A, Schmidt-Knosalla I, Heinemann T, Schlawinsky M, Blumberg RS, Volk HD, Utku N: Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice. Am J Transplant (2004) 4(4):505-514. • This study demonstrated that anti-TIRC7 mAb prevents rejection of heart allo-transplants and is of importance due to the short-time therapeutic intervention which induced CTLA-4 and anergy in vivo.
22. Kumamoto Y, Tamura A, Volk HD, Reinke P, Lohler J, Tullius SG, Utku N: TIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in rats. Transpl Immunol (2006) 16(3-4):238-244. •• This paper discusses antibody therapy targeting TIRC7 in combination with a calcineurin inhibitor FK-506 in organ transplantation. The results showed the dose reduction of FK-506 to prevent organ rejection and indicated the potential to diminish toxic side effects.
23. Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwin GC, Heinemann T, Loehler J, Blumberg RS, Volk HD: TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol (2004) 173(4):2342-2352. •• This study demonstrated that TIRC7 function is not only restricted to Th1 response, but also involves Th2, and T- and B-cell responses during immune activation.
24. Cantrell D: T cell antigen receptor signal transduction pathways. Annu Rev Immunol (1996) 14:259-274.
25. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson C, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1(5):405-413.
26. Thompson CB, Allison JP: The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 7(4):445-450.
27. Leung, HT, Bradshaw J, Cleaveland JS, Linsley PS: Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem (1995) 270(42):25107-25114.
28. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med (2005) 353(11):1114-1123. •• Along with reference [29 ••], this study demonstrated the importance and benefit of a negative regulatory pathway, CTLA-4, regulated in part via TIRC7, for the treatment of inflammation.
29. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 349(20):1907-1915. •• Along with reference [28 ••], this study demonstrated the importance and benefit of a negative regulatory pathway, CTLA-4, regulated in part via TIRC7, for the treatment of inflammation.
30. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3(5):541-547.
31. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science (1995) 270(5238):985-988.
32. Blin-Wakkach C, Wakkach A, Sexton PM, Rochet N, Carle GF: Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia (2004) 18(9):1505-1511.
33. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S et al: The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet (2001) 10(17):1767-1773.
34. Scimeca JC, Quincey D, Parrinello H, Romatet D, Grosgeorge J, Gaudray P, Philip N, Fischer A, Carle GF: Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat (2003) 21(2):151-157. • This paper describes the clinical manifestation of mutations observed in the TCIRG1 gene encoding both OC116 and TIRC7 proteins.
35. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W: Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the CICN7 chloride channel gene. Hum Mol Genet (2001) 10(25):2861-2867.
36. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD et al: Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet (2000) 25(3):343-346.
37. Blin-Wakkach C, Wakkach A, Quincey D, Carle GF: Interleukin-7 partially rescues B- lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220+ CD11b+ progenitors. Exp Hematol (2006) 34(7):851-859.
38. Weaver AL: The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (2004) 43(Suppl 3):17-23.
39. Svensson L, Jirholt J, Holmdahl R, Jansson L: B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol (1998) 111(3):521-526.
40. Gorman C, Leandro M, Isenberg D: B cell depletion in autoimmune disease. Arthritis Res Ther (2003) 5(Suppl 4):S17-S21.
41. Malmstrom V, Trollmo C, Klareskog L: Modulating co-stimulation: A rational strategy in the treatment of rheumatoid arthritis?Arthritis Res Ther (2005) 7(Suppl 2):S15-S20.
42. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nature (2002) 2(5):364-371. •• This paper describes the benefits of targeting the TNF α pathway in RA and pioneered the development of subsequent biological agents to target inflammatory pathways.
43. Glabinski AR, Bielecki B, Kawczak JA, Tuohy VK, Selmaj K, Ransohoff RM: Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity (2004) 37(6-7):465-471.
44. Marinova-Mutafchieva L, Williams RO, Mauri C, Mason LJ, Walmsley MJ, Taylor PC, Feldmann M, Maini RN: A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumour necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum (2000) 43(3):638-644.
45. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R: B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica (2002) 87(2):189-195.
46. Okamoto H, Kamatani N: Rituximab for rheumatoid arthritis. N Engl J Med (2004) 351(18):1909. •• This research describes the clinical outcome of B-cell targeting as a new and successful therapeutic approach in inflammation.
47. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 2(7):632-637.
48. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care (2001) 7(6):384-389.
49. Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR: Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection. Transplantation (1997) 64(10):1428-1432.
50. Büchler M, Hurault de Ligny B, Madec C, Lebranchu Y, French Thymoglobuline Pharmacovigilance Study Group: Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant (2003) 17(6):539-545.
51. Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science (1989) 243(4889):355-361.
52. Kita Y, Li XK, Ohba M, Funeshima N, Enosawa S, Tamura A, Suzuki K, Amemiya H, Hayashi S, Kazui T, Suzuki S: Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation (1999) 68(6):758-766.
53. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA (1997) 94(16):8789-8794.
54. Rothstein DM, Sayegh MH: T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev (2003) 196:85-108.
55. Pascual J, Marcen R, Ortuno J: Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab. Nephrol Dial Transplant (2001) 16(9):1756-1760.
56. Tomasoni S, Azzollini N, Casiraghi F, Capogrossi MC, Remuzzi G, Benigni A: CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol (2000) 11(4):747-752.
57. Chandraker A, Huurman V, Hallet K, Yuan X, Textor AJ, Park CH, Lu E, Zavazava N, Oaks M: CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation (2005) 79(8):897-903.
58. Tamura A, Milford EL, Utku N: TIRC7 pathway as a target for preventing allograft rejection. Drug News Perspect (2005) 18(2):103-108.
59. Shulzhenko N, Morgun A, Rampim GF, Franco M, Almeida DR, Diniz RV, Gerbase-DeLima M: Monitoring of intragraft and peripheral blood TIRC7 expression as a diagnostic tool for acute cardiac rejection in humans. Hum Immunol (2001) 62(4):342-347. • This study demonstrates the mRNA expression kinetics of TIRC7 in blood and tissue samples obtained after heart allograft transplantation. TIRC7 is induced in rejected allografts and reduced in blood mononuclear cells, supporting its potential as a diagnostic marker.